AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Infectious Vaccines Partnering Terms and Agreements Directory 2014-2019 - ResearchAndMarkets.com

May 23, 2019

DUBLIN--(BUSINESS WIRE)--May 23, 2019--

The “Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals.

The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 250 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials includes:

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2014
  • Analysis of infectious vaccines deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 250 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2014
  • The leading infectious vaccines deals by value since 2014
  • Includes adjuvant deals and alliances since 2014

Available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

1. Introduction

2. Trends in Infectious Vaccines dealmaking

2.1. Introduction

2.2. Infectious Vaccines partnering over the years

2.3. Most active Infectious Vaccines dealmakers

2.4. Infectious Vaccines partnering by deal type

2.5. Infectious Vaccines partnering by therapy area

2.6. Deal terms for Infectious Vaccines partnering

3. Leading Infectious Vaccines deals

3.1. Introduction

3.2. Top Infectious Vaccines deals by value

4. Most active Infectious Vaccines dealmakers

4.1. Introduction

4.2. Most active Infectious Vaccines dealmakers

4.3. Most active Infectious Vaccines partnering company profiles

5. Infectious Vaccines contracts dealmaking directory

5.1. Introduction

5.2. Infectious Vaccines contracts dealmaking directory

6. Infectious Vaccines dealmaking by technology type

7. Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Companies Mentioned

  • 2A
  • ABIVAX
  • Advanced Biological Laboratories
  • Aelix Therapeutics
  • Aeras
  • Aethlon Medical
  • Affinivax
  • Aldevron
  • American Gene Technologies
  • AnGes MG
  • Antigen Discovery
  • Antitope
  • Appili Therapeutics
  • Aptimmune Biologics
  • Aridis Pharmaceuticals
  • Ark Animal Health
  • Artes Biotechnology
  • Astellas Pharma
  • Avanzcare
  • Batavia Biosciences
  • Bavarian Nordic
  • Baxter International
  • Baylor College
  • Baylor College of Medicine
  • Baylor Institute for Immunology Research
  • Bill and Melinda Gates Foundation
  • BioClones
  • bioCSL
  • Bio Farma
  • Biokinetic Europe
  • Biomedical Advanced Research and Development Authority
  • BiondVax
  • BioNTech
  • BioSun Pharmed
  • Biothera
  • Bpifrance
  • BravoVax
  • Brighton Biotech
  • Broad Institute
  • Burnet Institute
  • Butantan Institute
  • Caliber Biotherapeutics
  • California Institute for Medical Researc
  • Calixar
  • CARB-X
  • Center for Genetic Engineering and Biotechnology (Cuba)
  • Centers for Disease Control and Prevention
  • Cevec Pharmaceuticals
  • Changchun BCHT Biotechnology
  • Children’s Hospital Boston
  • China National Biotech Group (CNBG)
  • Cilian
  • CiToxLAB
  • City of Hope
  • ClearPath
  • CMC Biologics
  • Coalition for Epidemic Preparedness Innovations
  • ContraFect
  • Corgenix Medical
  • Create Vaccine Company
  • Crucell
  • CryoPort
  • CSL
  • CureVac

Sample list of companies, more included in the report

For more information about this report visit https://www.researchandmarkets.com/r/tqw5jo

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005533/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/23/2019 11:15 AM/DISC: 05/23/2019 11:15 AM

http://www.businesswire.com/news/home/20190523005533/en

All contents © copyright 2019 The Associated Press.All rights reserved.